1 / 24

Scleroderma and the Kidney

Scleroderma and the Kidney. David Shure July 14, 2009. DD: Renal Failure. ATN Renal Scleroderma Crisis. Epidemiology. Prevalence: 19-75 cases per 100,000 Susceptibility Age: peak occurrence 35-65 F:M 7-12:1 Environmental Factors: infection Occupational exposure: silica dust

isra
Download Presentation

Scleroderma and the Kidney

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Scleroderma and the Kidney David Shure July 14, 2009

  2. DD: Renal Failure • ATN • Renal Scleroderma Crisis

  3. Epidemiology • Prevalence: 19-75 cases per 100,000 • Susceptibility • Age: peak occurrence 35-65 • F:M 7-12:1 • Environmental Factors: infection • Occupational exposure: silica dust • Usually occurs w/in 4-5 yrs of SSc onset

  4. Local vs Systemic Disease

  5. Classification • dcSSC: diffuse cutaneous SSc • lcSSc: limited cutaneous SSC • SSc sine scleroderma – internal organ involvement • Environmentally induced scleroderma • Overlap syndrome: ie MCTD

  6. Calcinosis cutis • Raynaud Phenomenon • Esophageal dysmotility • Sclerodactyly • Telangiectasia

  7. Pathogenesis • Complex and poorly understood • Immune activation • Inflammatory response • Vascular damage • Excessive synthesis EC matrix and collagen deposition • Hypothesis: interplay between early immunological events and vascular changes leading to generation of a pop of activated fibrogenic fibroblasts believed to be effector cells in disease

  8. Vascular and Endothelial Changes • Appear to precede other features of SSc • Vasoconstriction • ET-1: significantly elevated in SSc and assoc with pulm htn, may initiate fibrosis • Superoxide anions: released from endothelium neutralize NO • Defective vasculogenesis: fewer circulating endothelial ell precursors ie CD34+, CD133+ and VEGF type 2 • Pts with SSc have incr in endothelial cell surface expression of adhesion molecules and elevation in circulating levels of their soluble forms. Cytokine induced upregulation of adhesion molecules ie ICAM-1, VCAM-1, ELAM-1

  9. Autoantibodies • 75% pts with SSc have circulating autoantibodies • Topoisomerase I (anti-scl 70) • anti-topoisomerase antibodies highly specific for SSc, and correlate with greater risk for ILD and more extensive skin involvement • Centromere antigens (12-44%) • Anticentromere antibodies assoc with limited cutaneous involvement

  10. Fibrosis • Fibrosis gradually replaces vascular inflammatory phase and ultimately disrupts architecture of affected tissue • TGF-b • CTGF • PDGF

  11. TGF b • Main Cell Source: macrophages, fibroblasts, T/B cells, platelets, endothelial cells • Pathogenic relevance: • Induces proliferation fibroblasts and production CTGF and endothirlin-1 • Stimulates synthesis collagen, fibronectin • Inhibits EC matrix degradation by reduced synthesis of MMP and induction of TIMP-1 • Effect in SCL • Increased levels in skin • Elevated expression/ phosphorylation of smad2,3 effectors of TGF b signaling pathway

  12. Mechanism of Signal Transduction Mediated by Transforming Growth Factor {beta} (TGF-{beta}) Blobe G et al. N Engl J Med 2000;342:1350-1358

  13. CTGF • Cell source: fibroblasts, endothelial cells, smooth muscle cells • Pathogenic relevance: • induced by TGFb, IL-4, and VEGF • Induces proliferation and chemotaxis of fibroblasts and stimulates production of EC matrix • Effect in SCL • Elevated levels in serum • Incr gene expression in skin and in fibroblasts

  14. PDGF • Cell source: platelets, macrophages, endothelial cells, fibroblasts • Pathogenic Relevance: • Mitogen and chemoattractant for fibroblasts • Induces syntehsis of collagen, fibronectin, proteoglycans, • Stimulates secretion of TGF b type I, MCP-1, IL-6 • Effect in SCL • Elevated expression PDGN in skin • Incr levels in BAL

  15. Selective Up-Regulation of PDGFR by Fibroblasts in Scleroderma Tan F. N Engl J Med 2006;354:2709-2711

  16. SRC: Diagnosis • New/abrupt onset BP >150/85 • Progressive/sudden rise in creat • Additional findings • MAHA and thrombocytopenia • Acute retinal changes of malignant HTN • New onset proteinuria/ hematuria • Urine sediment is bland with limited but incr protein • MAHA/TMA • Characteristic changes on renal bx

  17. Renal Biopsy Subintimal Fibrin Deposition – Interlobular artery Muscular Renal Artery – Onion Skin thickening with complete obliteration of vascular lumen

  18. Fibrin Deposition

  19. Prevention/Treatment • Prevention: avoidance glucocorticoids • If left untreated, SRC can progress to ESRD over 1-2 months and death usually within 1 yr • Treatment: • Mainstay prompt control HTN, return to baseline bp in 72 hrs • Optimal anti-HTN is ACE-I ie captopril • Captopril? Advantage = rapid onset and short DOA allowing for more frequent titration • Also follow: plt count, LDH, Hb, haptoglobin, LDH for resolution of intravascular hemolysis • Indefinite continuation of ACE for bp control

  20. ACE Inhibitors • Retrospective & case-control studies show no efficacy in prevention of SRC • Prospective cohort study- treated vs. untreated: treated w/↑ recovery of renal fxn & ↑ survival at 1 yr (76% vs 15%)

  21. Long-term Outcomes of Scleroderma Reanl Crisis • Steen V, et al, Annals of Int Med, 2000 • Prospective observational cohort w5-10 yr f/u • 145 pts with SRC who received continuous ACE-I, and 662 pts with SCL who did not have renal crisis • Results: • At time of renal crisis, 75% pts had SCL sxs for <4 yrs • 61 % pts with SRC had good outcomes (55 received no HD, 34 received temp HD). Only 4% of later group progressed to ESRD • >1/2 of pts who began HD could dc it 3 to 18 mths later • Survival of pts in good outcome group was similar to pts with diffuse SCL without renal crisis

  22. Autologous non-myeloablative hematopoietic stem cell transplantation in pts with systemic sclerosis • Burt RK, et al 2007 Bone Marrow Transplantation • Phase I non-myeloablative autologous HSCT • 10 pts with SSc and poor prognostic features • PBCS mobilized with CY and G-CSF • PBSC graft re-infused after tx with non-myeloablative conditioning regimen • statistically significant improvement of modified Rodnan skin score, however cardiac, pulmonary function, and creat remained unchanged • F/U: 25 mths, overall and progression free survival rates are 90 and 70% • Concl: Autologous HSCT with non-myeloablative conditioning regimen may lead to improved skin flexibility similar to a myeloablative TBI , but without the toxicity and risks

More Related